Iterum Therapeutics plc
ITRM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | -0.11 | 0.05 | 0.08 |
| FCF Yield | -25.61% | -11.96% | -7.31% | -12.21% |
| EV / EBITDA | -6.64 | -10.49 | -15.52 | -10.38 |
| Quality | ||||
| ROIC | -28.01% | -19.28% | -12.59% | -8.85% |
| Gross Margin | 94.87% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.87 | 0.73 | 0.63 | 0.65 |
| Growth | ||||
| Revenue 3-Year CAGR | 730,514.36% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -65.44% | -55.16% | 28.05% | -59.28% |
| Safety | ||||
| Net Debt / EBITDA | -2.82 | -3.46 | -4.91 | -3.95 |
| Interest Coverage | -16.74 | -12.31 | -6.95 | -4.20 |
| Efficiency | ||||
| Inventory Turnover | 0.02 | 0.73 | 0.64 | 0.00 |
| Cash Conversion Cycle | 2,700.00 | -31.16 | 31.58 | 0.00 |